Roerig James L
Ment Health Clin. 2019 Nov 27;9(6):336-348. doi: 10.9740/mhc.2019.11.336. eCollection 2019 Nov.
Clozapine is established as the gold standard for antipsychotic treatment of patients suffering from treatment-resistant schizophrenia. Over virtually 3 decades, the level of inadequate response to clozapine was found to range from 40% to 60%. A heightened interest developed in the augmentation of clozapine to try to achieve response or maximize partial response. A large variety of drug groups have been investigated. This article focuses on the meta-analyses of these trials to discover reasonable evidence-based approaches to the management of patients not responding to clozapine.
氯氮平已被确立为治疗难治性精神分裂症患者抗精神病治疗的金标准。在近30年里，发现对氯氮平反应不足的比例在40%至60%之间。人们对增强氯氮平疗效以试图实现有效反应或使部分反应最大化的兴趣日益浓厚。已经对各种各样的药物组进行了研究。本文重点关注这些试验的荟萃分析，以发现合理的循证方法来管理对氯氮平无反应的患者。
